Analysis Date: 2025-12-12T10:22:26.240410 Trading Period: 2025-12-08 to 2025-12-19
Company: Corbus Pharmaceuticals Holdings, Inc. Sector: Healthcare | Industry: Biotechnology Current Price: $9.68 Market Cap: $169,913,392 Beta: 2.72 Avg Volume: 451,115 Website: https://www.corbuspharma.com
Description: Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a highly peripherally re...
Action: HOLD Confidence: 52.1/100 Position Size: 0.0% of portfolio
Rationale: Mixed signals (composite: 52.1/100, risk: LOW).
Key Risks:
Passed Filters: ✓ Yes Notes: Passed all screening filters
Composite Score: 3.20/5.0 Percentile Rank: 50%
Factor Scores:
Setup Score: 2/8 Setup Notes: High volume today (10.0x)
Price Levels:
Momentum & Volume:
Risk Level: LOW Confidence: 70.0/100 Total Red Flags: 2 Earnings Risk: No
Stock-Specific Red Flags:
This report is generated by PM automated research system. Always perform your own due diligence before trading.